{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:05:45Z","timestamp":1792044345278,"version":"4.4.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Radiotherapy, conventional or radiosurgery, has been used to control prolactin secretion and tumour growth in prolactinomas both as part of multimodal therapy or rarely as primary treatment. However, considering the radiotherapy side effects, notably hypopituitarism, as opposed to the high efficacy and low toxicity of dopamine agonists (DA) treatment and neurosurgery, radiotherapy is recommended mostly for patients with aggressive or high-risk prolactinomas or in those resistant or intolerant to medical therapy, usually after surgical failure. We provide an overview of the published literature on the efficacy and toxicity of radiotherapy (conventional fractionated or radiosurgery), in aggressive, high-risk, or DA resistant prolactinomas. Radiotherapy has shown a good efficacy and a reasonable toxicity profile in prolactinomas where other treatment modalities failed. In aggressive and high-risk prolactinomas, the cumulative percentage for tumour control (reduction plus stable) ranged from 68% to 100%. Most studies reported global hormonal control rates over 50%. In resistant prolactinomas, the global secretion control rate (on, but also off DA) ranged from 28% to 89%\u2013100%; in most studies over 80%. The 5-year rate of hypopituitarism was around 12%\u201325%. To date there are no controlled study on the use of radiotherapy as a prophylactic treatment in patients with clinical, radiological or pathological markers of aggressiveness. In conclusion, our review supports the use of radiotherapy in patients with growing, clinically aggressive or truly DA resistant prolactinomas. In patients with high-risk or invasive prolactinomas or in those harboring pathological markers of aggressiveness, the prophylactic use of radiotherapy should be individualized.<\/jats:p>","DOI":"10.1093\/ejendo\/lvad044","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T16:35:58Z","timestamp":1680021358000},"page":"R88-R97","source":"Crossref","is-referenced-by-count":16,"title":["Radiotherapy in aggressive or dopamine agonists resistant prolactinomas; is it still worthwhile?"],"prefix":"10.1093","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-3523","authenticated-orcid":false,"given":"Dan Alexandru","family":"Niculescu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Carol Davila University of Medicine and Pharmacy , Bucharest , Romania"},{"name":"Department of Pituitary and Neuroendocrine Disorders, C. I. Parhon National Institute of Endocrinology , Bucharest , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-5619","authenticated-orcid":false,"given":"Monica Livia","family":"Gheorghiu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Carol Davila University of Medicine and Pharmacy , Bucharest , Romania"},{"name":"Department of Thyroid Disorders, C. I. Parhon National Institute of Endocrinology , Bucharest , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Poiana","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Carol Davila University of Medicine and Pharmacy , Bucharest , Romania"},{"name":"Department of Pituitary and Neuroendocrine Disorders, C. I. Parhon National Institute of Endocrinology , Bucharest , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"issue":"2","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical biology of the pituitary adenoma","volume":"43","author":"Melmed","year":"2022","journal-title":"Endocr Rev"},{"issue":"5","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"issue":"3","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-21-0977","article-title":"Italian Association of clinical endocrinologists (AME) and international chapter of clinical endocrinology (ICCE). position statement for clinical practice: prolactin-secreting tumors","volume":"186","author":"Cozzi","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1055\/a-1066-4592","article-title":"Updates in the medical treatment of pituitary adenomas","volume":"52","author":"Gheorghiu","year":"2020","journal-title":"Horm Metab Res"},{"issue":"5","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-11-1000","article-title":"Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients","volume":"166","author":"Primeau","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1210\/jc.2009-1191","article-title":"Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up","volume":"95","author":"Raverot","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1530\/EJE-21-0293","article-title":"Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study","volume":"185","author":"Baussart","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","article-title":"Surgery as a viable alternative first-line treatment for prolactinoma patients. a systematic review and meta-analysis","volume":"105","author":"Zamanipoor Najafabadi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11102-011-0348-6","article-title":"Radiotherapy for prolactin-secreting pituitary tumors","volume":"15","author":"Olsen","year":"2012","journal-title":"Pituitary"},{"issue":"7","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1210\/jc.2011-0251","article-title":"Radiation therapy in the management of pituitary adenomas","volume":"96","author":"Loeffler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.rpor.2014.09.004","article-title":"Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas","volume":"21","author":"Minniti","year":"2016","journal-title":"Reports Pract Oncol Radiother"},{"issue":"4","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4183\/aeb.2017.476","article-title":"Stereotactic radiation therapy in pituitary adenomas, is it better than conventional radiation therapy?","volume":"13","author":"Gheorghiu","year":"2017","journal-title":"Acta Endocrinol (Bucharest, Rom 2005)"},{"issue":"3","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.radonc.2009.09.011","article-title":"Radiotherapy for pituitary adenomas: long-term efficacy and toxicity","volume":"93","author":"Erridge","year":"2009","journal-title":"Radiother Oncol"},{"issue":"9254","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(00)04006-X","article-title":"Association between premature mortality and hypopituitarism","volume":"357","author":"Tomlinson","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0360-3016(99)00159-5","article-title":"The incidence of cerebrovascular accidents in patients with pituitary adenoma","volume":"45","author":"Brada","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1210\/jc.2004-1152","article-title":"Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years","volume":"90","author":"Minniti","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1210\/jc.2016-3402","article-title":"Especially at young age, increases the risk for de novo brain tumors in patients treated for pituitary\/sellar lesions","volume":"102","author":"Burman","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3171\/2019.4.JNS183443","article-title":"The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study","volume":"133","author":"Hung","year":"2019","journal-title":"J Neurosurg"},{"issue":"3","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3171\/2021.2.JNS204440","article-title":"Stereotactic radiosurgery for secretory pituitary adenomas: systematic review and international stereotactic radiosurgery society practice recommendations","volume":"136","author":"Mathieu","year":"2021","journal-title":"J Neurosurg"},{"issue":"19","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.3390\/cancers13194998","article-title":"Gamma knife radiosurgery for pituitary tumors: a systematic review and meta-analysis","volume":"13","author":"Albano","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11154-020-09543-y","article-title":"Radiation techniques in aggressive pituitary tumours and carcinomas","volume":"21","author":"Castinetti","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000499382","article-title":"Clinical, pathological, and molecular factors of aggressiveness in lactotroph tumours","volume":"109","author":"Trouillas","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"3","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","article-title":"Overview of the 2017 WHO classification of pituitary tumors","volume":"28","author":"Mete","year":"2017","journal-title":"Endocr Pathol"},{"issue":"1","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr Pathol"},{"issue":"1","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"3","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11060-013-1270-8","article-title":"Management of medically refractory prolactinoma","volume":"117","author":"Molitch","year":"2014","journal-title":"J Neurooncol"},{"issue":"1","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11102-005-5085-2","article-title":"Pharmacologic resistance in prolactinoma patients","volume":"8","author":"Molitch","year":"2005","journal-title":"Pituitary"},{"issue":"5","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients","volume":"160","author":"Delgrange","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"R213","DOI":"10.1530\/EJE-14-0013","article-title":"Therapy of endocrine disease: the challenges in managing giant prolactinomas","volume":"170","author":"Maiter","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/s11102-015-0658-1","article-title":"Gamma knife radiosurgery for medically and surgically refractory prolactinomas: long-term results","volume":"18","author":"Cohen-Inbar","year":"2015","journal-title":"Pituitary"},{"issue":"1","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12020-016-1129-9","article-title":"Long-term outcome of multimodal therapy for giant prolactinomas","volume":"55","author":"Andujar-Plata","year":"2017","journal-title":"Endocrine"},{"key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jocn.2021.01.025","article-title":"Gamma knife radiosurgery for high-risk lactotroph adenomas: long-term results","volume":"86","author":"Kara","year":"2021","journal-title":"J Clin Neurosci"},{"issue":"4","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11102-019-00971-x","article-title":"Role of gamma knife radiosurgery in the treatment of prolactinomas","volume":"22","author":"Je\u017ekov\u00e1","year":"2019","journal-title":"Pituitary"},{"issue":"6","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1227\/01.NEU.0000124750.13721.94","article-title":"Gamma knife radiosurgery for benign cavernous sinus tumors: quantitative analysis of treatment outcomes","volume":"54","author":"Kuo","year":"2004","journal-title":"Neurosurgery"},{"issue":"Suppl. 3","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3171\/jns.2000.93.supplement_3.0014","article-title":"Gamma knife radiosurgery for prolactinomas","volume":"93","author":"Landolt","year":"2000","journal-title":"J Neurosurg"},{"issue":"5","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s007010050121","article-title":"Gamma-knife surgery for secreting pituitary adenomas","volume":"140","author":"Morange-Ramos","year":"1998","journal-title":"Acta Neurochir (Wien)"},{"issue":"1","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-8140(96)91807-1","article-title":"Role of radiation therapy in clinical hormonally-active pituitary adenomas","volume":"41","author":"Tsang","year":"1996","journal-title":"Radiother Oncol"},{"issue":"6","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2265.1986.tb01664.x","article-title":"The long-term effects of megavoltage radiotherapy as sole or combined therapy for large prolactinomas: studies with high definition computerized tomography","volume":"24","author":"Johnston","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11102-012-0376-x","article-title":"Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas","volume":"16","author":"Liu","year":"2013","journal-title":"Pituitary"},{"issue":"2","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2265.2012.04351.x","article-title":"Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome","volume":"77","author":"Iglesias","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.wneu.2010.05.007","article-title":"Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas","volume":"74","author":"Tanaka","year":"2010","journal-title":"World Neurosurg"},{"issue":"1","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2009.03755.x","article-title":"Outcome of fractionated stereotactic radiotherapy in patients with pituitary adenomas resistant to conventional treatments: a 5.25-year follow-up study","volume":"73","author":"Schalin-J\u00e4ntti","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1227\/01.NEU.0000223445.22938.BD","article-title":"Gamma knife radiosurgery for medically and surgically refractory prolactinomas","volume":"59","author":"Pouratian","year":"2006","journal-title":"Neurosurgery"},{"issue":"4","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/cncr.22860","article-title":"The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution","volume":"110","author":"Kong","year":"2007","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000056444","article-title":"A six year experience with the postoperative radiosurgical management of pituitary adenomas","volume":"72","author":"Mokry","year":"1999","journal-title":"Stereotact Funct Neurosurg"},{"issue":"Suppl. 3","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3171\/jns.2000.93.supplement_3.0010","article-title":"Gamma knife radiosurgery as a primary treatment for prolactinomas","volume":"93","author":"Pan","year":"2000","journal-title":"J Neurosurg"},{"issue":"2-3","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000048393","article-title":"Gamma knife radiosurgery as a primary surgical treatment for hypersecreting pituitary adenomas","volume":"75","author":"Zhang","year":"2000","journal-title":"Stereotact Funct Neurosurg"},{"issue":"2","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11154-020-09562-9","article-title":"Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's Questions","volume":"21","author":"Trouillas","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"101713","DOI":"10.1016\/j.beem.2022.101713","article-title":"Temozolomide in aggressive pituitary tumours and pituitary carcinomas","volume":"36","author":"McCormack","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"700007","DOI":"10.3389\/fneur.2021.700007","article-title":"Clinical efficacy of temozolomide and its predictors in aggressive pituitary tumors and pituitary carcinomas: a systematic review and meta-analysis","volume":"12","author":"Luo","year":"2021","journal-title":"Front Neurol"},{"key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"4618664","DOI":"10.1155\/2022\/4618664","article-title":"A retrospective trail investigating temozolomide neoadjuvant chemotherapy combined with radiotherapy in low-grade pituitary tumors","volume":"2022","author":"Cui","year":"2022","journal-title":"J Oncol"},{"issue":"2","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10143-010-0285-2","article-title":"Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature","volume":"34","author":"Sun","year":"2010","journal-title":"Neurosurg Rev"},{"issue":"8","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S2213-8587(22)00160-7","article-title":"Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance","volume":"10","author":"Hamblin","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023041714284461200_","doi-asserted-by":"crossref","DOI":"10.1227\/neu.0000000000002347","article-title":"Effects of neuroanatomic structural distances on pituitary function after stereotactic radiosurgery: a multicenter study","author":"Ironside","year":"2023","journal-title":"Neurosurgery"},{"issue":"3","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3171\/2021.3.JNS203812","article-title":"Dose to neuroanatomical structures surrounding pituitary adenomas and the effect of stereotactic radiosurgery on neuroendocrine function: an international multicenter study","volume":"136","author":"Pomeraniec","year":"2021","journal-title":"J Neurosurg"},{"issue":"3","key":"2023041714284461200_","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-21-0462","article-title":"ESE Clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy","volume":"185","author":"Luger","year":"2021","journal-title":"Eur J Endocrinol"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvad044\/49676701\/lvad044.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/188\/4\/R88\/49974418\/lvad044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/188\/4\/R88\/49974418\/lvad044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T17:06:47Z","timestamp":1702141607000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/188\/4\/R88\/7091429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvad044","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,5]]},"published":{"date-parts":[[2023,3,28]]}}}